The Department of Health and Human Services July 1 ordered an additional 2.5 million doses of Bavarian Nordic's JYNNEOS, an FDA-licensed vaccine for prevention of smallpox and monkeypox, for use in responding to current or future monkeypox outbreaks and as part of the nation’s smallpox preparedness. Deliveries from this latest order will begin arriving at the Strategic National Stockpile later this year and will continue through early 2023. 
  
This order brings the total vaccine doses to be delivered in 2022 and 2023 to more than 4 million. As of July 1, the CDC has reported approximately 460 U.S. cases of monkeypox. 
 

Related News Articles

Headline
Jurisdictions that have used 90% of their JYNNEOS monkeypox vaccine supply and are administering the vaccine intradermally to adults can begin ordering…
Headline
The Department of Health and Human Services Monday began accepting orders from states and other jurisdictions for a portion of 442,000 additional doses of the…
Headline
The Food and Drug Administration Friday said it does not recommend screening or testing blood donors for the monkeypox virus, given “the robustness” of…
Headline
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the…
Headline
The Food and Drug Administration yesterday issued an emergency use authorization allowing health care providers to administer the JYNNEOS vaccine intradermally…
Headline
Health and Human Services Secretary Xavier Becerra today took action that will allow the Food and Drug Administration Commissioner to grant emergency use…